Thermal ablation of Barrett's esophagus: A heated debate

American Journal of Gastroenterology

Volumn 101, Issue 8, 2006, Pages 1770-1772

  Spechler, Stuart J ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; BLEEDING; CANCER RISK; DATA ANALYSIS; DYSPLASIA; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ARGON; BARRETT ESOPHAGUS; ESOPHAGOSCOPY; HUMANS; LASER COAGULATION; POSTOPERATIVE COMPLICATIONS; RISK;

EID: 33746708126     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00706.x     Document Type: Review

References (14)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.
2. Sampliner RE. The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
3. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Clinical applications. JAMA 2002;287:1982-6.
4. Wolfsen HC. Endoprevention of esophageal cancer: Endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices 2005;2:713-23.
5. Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett's esophagus: A pilot study. Gastrointest Endosc 2005;62:842-8.
6. Overholt BF, Lightdale CJ, Wang KK, et al. International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: International, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98.
7. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574-7.
8. Garewal HS, Ramsey L, Sampliner RE, et al. Post-ablation biomarker abnormalities in Barrett's esophagus (BE): Are we increasing the cancer risk? Gastroenterology 2001;120:A79.
9. Kahaleh M, Van Laethem JL, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002;34:950-5.
10. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000;51:659-63.
11. Madisch A, Miehlke S, Bayerdorffer E, et al. Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. World J Gastroenterol 2005;11:1182-6.
12. Manner H, May A, Miehlke S, et al. Ablation of non-neoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. Am J Gastroenterol 2006;101:1762-9.
13. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
14. Schoenfeld P, Cook D, Hamilton F, et al. An evidence-based approach to gastroenterology therapy. Gastroenterology 1998;114:1318-25.